1. 1184PA phase I/II safety study of tisotumab vedotin (HuMax®-TF-ADC) in patients with solid tumors. (18th September 2017) Authors: Chenard-Poirier, M.; Hong, D.S.; Coleman, R.; de Bono, J.; Mau-Sorensen, M.; Collins, D.; Lisby, S.; Basse, L.; Lassen, U. Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2361 Modified FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for gemcitabine-resistant or -refractory advanced pancreatic cancer. (September 2015) Authors: Lee, S.C.; Lee, K.; Bae, S.B.; Jo Kim, Han; Oh, S.Y.; Song, S.Y.; Hong, D.S.; Jung Kim, Hyun; Yoon, J.; Lim, D.H.; Lee, S.I.; Won, J.H.; Lee, N.; Kim, K.; Lee, H.W.; Lee, H.R.; Nam, E.M.; Jang, J.S.; Hwang, I.G.; Kang, J.H. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Circulating Tumor DNA Dynamics Predict Outcomes of Systemic Therapy in Patients with Advanced Cancers. (October 2020) Authors: Gouda, M.; Huang, H.; Piha-Paul, S.; Call, S.G.; Karp, D.; Fu, S.; Naing, A.; Subbiah, V.; Pant, S.; Tsimberidou, A.M.; Hong, D.S.; Rodon, J.; Meric-Bernstam, F. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. (February 2017) Authors: Hong, D.S.; Dowlati, A.; Burris, H.A.; Lee, J.J.; Brose, M.S.; Farago, A.F.; Bauer, T.M.; Taylor, M.; Shaw, A.T.; Smith, S.; Nanda, N.; Cruikshank, S.; Cox, M.C.; Doebele, R.C. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations. (October 2022) Authors: Ngoi, N.; Pilie, P.G.; Piha-Paul, S.A.; Dumbrava, E.E.; Fu, S.; Hong, D.S.; Karp, D.D.; Naing, A.; Pant, S.; Rodon Ahnert, J.; Subbiah, V.; Tsimberidou, A.M.; Salguero, C.; Brown, C.V.; Hoadley, W.E.; Johnson, A.; Yuan, Y.; Westin, S.N.; Meric-Bernstam, F.; Yap, T.A. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Drug development in the MD Anderson Cancer Center (MDACC) Clinical Translational Research Center (CTRC) – 2011–2015: The challenge of precision medicine in a very broad playing field. (December 2016) Authors: Dembla, V.; Ray, D.; Lockett, P.; Fullmer, C.; Subramanian, H.; Subbiah, V.; Fu, S.; Janku, F.; Tsimberidou, A.M.; Naing, A.; Piha-Paul, S.A.; Hong, D.S.; Pant, S.; Miller, V.A.; Lim, J.; Le, H.; Karp, D.D. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. (October 2022) Authors: Yap, T.A.; Ngoi, N.; Dumbrava, E.E.; Karp, D.D.; Rodon Ahnert, J.; Fu, S.; Hong, D.S.; Naing, A.; Pant, S.; Piha-Paul, S.A.; Subbiah, V.; Tsimberidou, A.M.; Dufner, D.; Rhudy, J.; Gore, S.; Ivy, S.P.; Yuan, Y.; Westin, S.N.; Mills, G.B.; Meric-Bernstam, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗